Efficacy of Eflornithine Hydrochloride Cream in the Treatment of Melasma: A Randomized, Double-blinded, Split-face Controlled Study

National Skin Centre

Status and phase

Completed

Phase 2

Conditions

Melasma

Treatments

Drug: Hydroquinone cream

Drug: Eflornithine hydrochloride cream

Study type

Interventional

Funder types

NETWORK

Identifiers

NCT06957834

2019/00399

Details and patient eligibility

About

The goal of this clinical trial is to learn if Eflornithine hydrochloride cream works to treat melasma in adults, in comparison to Hydroquinone cream. It will also learn about the safety of Eflornithine hydrochloride cream. The main questions it aims to answer are:

Does Eflornithine hydrochloride improve melasma assessment scores over a 3-month duration compared to Hydroquinone cream?
What side effects might patients get while using Eflornithine hydrochloride cream?

Participants will:

Apply both Eflornithine hydrochloride and Hydroquinone creams on separate halves of their faces every day for 3 months.
Visit the clinic once at the 2-month mark and once at the 3-month mark for checkups and tests.

Enrollment

20 patients

Sex

All

Ages

25 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of melasma
Fitzpatrick Type III or IV
Able to provide informed consent

Exclusion criteria

Pregnant or lactating patients
Patients with difficulty adhering to regular topical treatments
Patients with known contact allergies to any of the ingredients in the topical medications used in the study